 HOUSTON, July 31, 2020 GLOBE NEWSWIRE -- Bellicum Pharmaceuticals, Inc. NASDAQ:BLCM, a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to two new employees consisting of an aggregate of 3,520 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of July 31, 2020. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635c4. The stock options have an exercise price of 6.71 per share and vest over four years, with 25 of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 148 of the shares vesting monthly thereafter, subject to the new employees continued service relationship with the Company. The stock options are subject to the terms and conditions of the Companys 2019 Equity Incentive Plan and a stock option agreement covering the grant.About Bellicum PharmaceuticalsBellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The companys next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and CAR-NK cell therapies. Bellicums GoCAR-T product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at Source: Bellicum PharmaceuticalsInvestors: Robert H. Uhl Managing Director Westwicke ICR 858-356-5932 